السلام عليكم
سعر السهم 1.03
BUSINESS WIRE)--Jan. 24, 2006--Axonyx Inc. (NASDAQ: AXYX - News) announced today completion of the ascending single dose Phase I trial with Posiphen(TM), in clinical development for the treatment of Alzheimer's disease progression.
بالتوفيق للجميع
سعر السهم 1.03
BUSINESS WIRE)--Jan. 24, 2006--Axonyx Inc. (NASDAQ: AXYX - News) announced today completion of the ascending single dose Phase I trial with Posiphen(TM), in clinical development for the treatment of Alzheimer's disease progression.
بالتوفيق للجميع
